Syndax Pharmaceuticals In... (SNDX)
NASDAQ: SNDX
· Real-Time Price · USD
9.21
0.02 (0.22%)
At close: Jun 24, 2025, 3:59 PM
9.22
0.16%
After-hours: Jun 24, 2025, 05:58 PM EDT
Syndax Pharmaceuticals Revenue Breakdown
| Period Ending | Dec 31, 2024 |
|---|---|
| Milestone Revenue Revenue | 16M |
| Milestone Revenue Revenue Growth | n/a |
| Net Product Revenues Revenue | 7.68M |
| Net Product Revenues Revenue Growth | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 41.03M | 37.69M | 31.11M | 29.06M | 23.02M | 22.78M | 17.27M | 14.91M | 11.96M | 10.19M | 8.24M | 7.99M | 6.84M | 6.93M | 6.8M | 5.84M | 5.67M | 4.72M | 5.82M | 6.05M | 5.92M | 5.08M | 3.6M | 3.46M | 3.91M | 3.89M | 4.13M | 4.48M | 4.79M | 4.08M | 3.56M | 4.29M | 3.93M | 2.97M | 3.27M | 2.81M | 4.27M | 2.4M | 3.19M | 3.29M | 2.71M |
| Selling, General, and Administrative Revenue Growth | +8.86% | +21.17% | +7.04% | +26.23% | +1.07% | +31.91% | +15.78% | +24.69% | +17.36% | +23.69% | +3.13% | +16.88% | -1.31% | +1.85% | +16.42% | +3.00% | +20.22% | -18.99% | -3.67% | +2.18% | +16.41% | +41.00% | +4.10% | -11.45% | +0.49% | -5.65% | -7.90% | -6.51% | +17.34% | +14.59% | -16.85% | +9.03% | +32.23% | -9.09% | +16.42% | -34.27% | +78.22% | -24.98% | -2.83% | +21.28% | n/a |
| Research and Development Revenue | 61.64M | 65.53M | 70.97M | 48.65M | 56.49M | 55.13M | 39.09M | 34.76M | 34.05M | 31.84M | 26.9M | 29.73M | 30.02M | 23.9M | 25.61M | 16.87M | 21.87M | 15.52M | 14.41M | 10.94M | 9.56M | 9.5M | 9.92M | 12.29M | 11.28M | 15.82M | 14.1M | 14.85M | 15.34M | 16.6M | 12.19M | 9.86M | 9.55M | 8.47M | 12.27M | 6.13M | 4.79M | 2.59M | 2.97M | 2.27M | 1.72M |
| Research and Development Revenue Growth | -5.94% | -7.67% | +45.87% | -13.87% | +2.47% | +41.03% | +12.44% | +2.08% | +6.95% | +18.36% | -9.53% | -0.96% | +25.62% | -6.66% | +51.78% | -22.86% | +40.90% | +7.73% | +31.66% | +14.44% | +0.63% | -4.24% | -19.26% | +8.96% | -28.71% | +12.25% | -5.09% | -3.18% | -7.59% | +36.19% | +23.59% | +3.25% | +12.72% | -30.96% | +100.20% | +28.10% | +85.00% | -12.84% | +30.69% | +31.80% | n/a |